Join Quanterix at the Alzheimer’s Association International Conference (AAIC) 2024 in Philadelphia, from July 28 to August 1. Visit us at booth #730 to explore our groundbreaking biomarker technology that is transforming Alzheimer’s and dementia research. Our ultra-sensitive digital immunoassay platform enables earlier diagnosis and the development of targeted therapies.

Meet our team of experts and engage in insightful discussions about the future of dementia care. The exhibit hall will be open from July 28-31, providing ample opportunity to discover how Quanterix is contributing to advancements in the field. Stay tuned for more details on our sponsorship of this event.

Don’t miss this chance to connect with thought leaders and learn about the latest innovations in dementia science.

Book a Meeting Now

Product Theater Presentation

The new normal – Detecting Alzheimer’s disease pathology through blood tests

July 29 at 10:30 am 
Exhibit Hall, booth #1017 

Finding new ways to diagnose Alzheimer’s disease is more crucial than ever, as new treatments, such as disease-modifying drugs, are most effective when administered early in the disease’s progression. Current standard methods, including PET imaging and cerebrospinal fluid (CSF) collection via lumbar puncture, are expensive and highly invasive, resulting in many cases going undiagnosed. More affordable and accessible methods, such as blood tests, could enable more widespread screening and monitoring of patients with (suspected) Alzheimer’s disease. A recent breakthrough involves plasma phosphorylated tau 217 (p-tau 217), which has been shown to perform equally well as CSF analysis in detecting Alzheimer’s disease. Additionally, new techniques that address the drawbacks of venous blood sampling, such as blood collection via a simple finger prick and the use of dried-blood spots, could play a decisive role in advancing these developments, enabling regular and personalized patient management and the investigation of previously neglected (research) areas. Simoa ultrasensitive technology is crucial in the development of these innovative diagnostic tools.

Meet the Speakers

Hanna Huber, PhD

Registered nurse and postdoctoral researcher, Department Neurochemistry, University Gothenburg, Sweden

Dr. Hanna Huber is a registered nurse and postdoctoral researcher at the Department Neurochemistry at the University Gothenburg, Sweden, in the group of Professor Henrik Zetterberg and Kaj Blennow, and the German Center for Neurodegenerative Diseases in Bonn, Germany, in the group of Professor Anja Schneider. She received her PhD in Nutrition Science in 2023 from the University of Bonn, Germany. Her postdoctoral research focuses on biofluid analysis for Alzheimer’s disease and the impact of external influencing factors, such as diet. Moreover, she developed a method for detecting biomarkers related to Alzheimer’s disease and other neurological disorders in dried blood spots obtained from a finger prick, which holds high potential for remote research settings, therapeutics trials and the clinical use of blood biomarkers.

Mark Roskey, PhD

Chief Science and Collaboration Officer, Quanterix

Mark joined Quanterix in 2014 as the Vice President and General Manager of Applications and Reagents. He has more than 25 years of experience in the life science industry focusing on product R&D, applications development, strategic sales and marketing, and overall business management for complex biological solutions and automated instrument systems. Mark joined Quanterix from PerkinElmer’s LST division where he was VP/GM of the America’s Sales and Service organization. Prior to PerkinElmer, Mark held senior-level commercial and technical positions at Caliper Life Sciences, which was acquired by PerkinElmer in 2011.

Mark holds a Ph.D. in Microbiology from the University of Notre Dame and completed a postdoctoral fellowship in Molecular Immunobiology at the Harvard Medical School.